News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Insulet Corporation Appoints Tracey H. Wielinski as VP, Global Regulatory/Clinical Affairs and Quality Assurance


1/24/2013 8:36:56 AM

BEDFORD, MA--(Marketwire - January 23, 2013) - Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced the appointment of Tracey H. Wielinski as Vice President, Global Regulatory/Clinical Affairs and Quality Assurance. Ms. Wielinski brings two decades of experience in quality assurance, regulatory and clinical affairs across a wide range of products in the healthcare industry, including in diabetes devices.

"Tracey is a highly accomplished quality assurance and regulatory affairs executive and we are very pleased to welcome her to Insulet's management team," said Duane DeSisto, President and Chief Executive Officer of Insulet. "Demand for the easy-to-use OmniPod insulin pump continues to grow around the world. Tracey's successful track record in global quality assurance, as well as her expertise in regulatory and clinical affairs, will be an asset to Insulet as we continue to advance our technology."

Most recently, Ms. Wielinski served as President and CEO of Qualtra Consulting, a medical device consulting firm specializing in regulatory and clinical affairs and quality system management. From 2008 to 2011, she was with ElectroSonics Medical, serving as Vice President, Clinical and Regulatory Affairs. Previously, Ms. Wielinski was with DX Tech, where she was Vice President, Regulatory Affairs and Quality Assurance. Her prior experience includes roles as Vice President, Regulatory Affairs and Quality Assurance at Rapid Micro Biosystems and Vice President, Corporate Quality and Compliance and Chief Compliance Officer for Oscient Pharmaceuticals. From 1997 to 2004, she held a variety of progressive QARA management roles at Abbott Laboratories/Medisense Products, Biomec, Inc. and Steris Corp. Ms. Wielinski holds a B.A. in Biology and Communications from the University of Toledo, and a M.S. in Health Product Regulation from Regis College.

About Insulet Corporation
Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and fully-automated cannula insertion. Insulet's subsidiary, Neighborhood Diabetes, is a leading distributor for diabetes products and supplies, delivered through a high touch customer service model. Founded in 2000, Insulet Corporation is based in Bedford, Mass.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws, including the expected closing date of this offering. These forward-looking statements are based on Insulet's current expectations and beliefs concerning future developments and their potential effects on it. There can be no assurance that future developments affecting it will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties described in the section entitled "Risk Factors" in Insulet's Annual Report on Form 10-K for the year ended December 31, 2011 and Item 1A in Insulet's Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, and in its other filings from time to time filed with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.


Contact:
Stephanie Marks for Insulet Corporation
ir@insulet.com
877-PODD-IR1 (877-763-3471)


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES